Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Altea gains US grant for insulin delivery device:

This article was originally published in Clinica

Executive Summary

Altea Development has received a phase II grant from the US National Institute of Diabetes and Digestive and Kidney Diseases to assess its MicroPor system for the noninvasive delivery of insulin. The Atlanta, Georgia firm will use the $944,000 grant to develop the device for the painless delivery of insulin as either a basal infusion throughout the day or as an on-demand bolus at mealtime. The MicroPor technology is a patch-based system that creates microscopic pores in the outermost skin layer to enable the systemic uptake of topically applied drugs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel